Trial Profile
Short-term Endothelin A Receptor Blockade in Patients With On-pump Coronary Artery Bypass Grafting
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs PMZ-2123 (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- 06 Aug 2020 Planned number of patients changed from 120 to 88.
- 06 Aug 2020 Status changed from recruiting to discontinued.
- 15 Aug 2012 New trial record